InsidersTradesSigma
Track the Nexalin Technology, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Nexalin Technology, Inc. has published 28 reports. Market capitalisation: €9.9m. The latest transaction was filed on 30 September 2025 (Attribution). Among the most active insiders: Owens David. The full history is accessible without an account.
28
Insider Decl.
n/a
Thresholds
€463,130
20 ops.
Buy Volume
n/a
n/a
Sell Volume
49Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 30 September 2025
Declarations28 total
36,459 shares0Common stockSEC:0001829126-25-007777:0
36,459 shares0Common stockSEC:0001829126-25-007775:0
83,333 shares0Common StockSEC:0001829126-25-007778:0
6,000 shares@ US$2.20100.0% of flowCommon StockSEC:0001829126-25-001766:0
Canonical exit: 10 Jun 2025 (T+90)
1,000 shares@ US$3.109.7% of flowCommon stockSEC:0001829126-25-000724:0
Canonical exit: 5 May 2025 (T+90)
1,000 shares@ US$2.989.4% of flowCommon stockSEC:0001829126-25-000672:0
Canonical exit: 5 May 2025 (T+90)
1,500 shares@ US$2.7012.6% of flowCommon stockSEC:0001829126-25-000542:0
Canonical exit: 28 Apr 2025 (T+90)
2,000 shares@ US$2.5015.8% of flowCommon stockSEC:0001829126-25-000368:0
Canonical exit: 13 Apr 2025 (T+90)
500 shares@ US$2.193.3% of flowCommon stockSEC:0001829126-24-007091:0
Canonical exit: 26 Jan 2025 (T+90)
700,000 shares0Common StockSEC:0001829126-24-006598:0
49,838 shares0Common stockSEC:0001829126-24-006597:0
700,000 shares0Common StockSEC:0001829126-24-006465:0
1,000 shares@ US$0.952.8% of flowCommon stockSEC:0001829126-24-005573:0
Canonical exit: 11 Nov 2024 (T+90)
1,000 shares@ US$1.755.3% of flowCommon stockSEC:0001829126-24-004517:0
Canonical exit: 26 Sept 2024 (T+90)
1,619 shares@ US$0.713.5% of flowCommon stockSEC:0001829126-24-004353:0
Canonical exit: 16 Sept 2024 (T+90)
2,000 shares@ US$0.653.9% of flowCommon stockSEC:0001829126-24-004108:0
Canonical exit: 8 Sept 2024 (T+90)
25,000 shares@ US$4.1547.6% of flowCommon StockSEC:0001829126-23-004519:0
Canonical exit: 14 Dec 2022 (T+90)
2,500 shares@ US$4.1550.0% of flowCommon StockSEC:0001829126-23-004518:0
Canonical exit: 15 Dec 2022 (T+90)
2,500 shares@ US$4.1550.0% of flowCommon StockSEC:0001829126-23-004520:0
Canonical exit: 15 Dec 2022 (T+90)
9,500 shares@ US$1.126.8% of flowCommon StockSEC:0001829126-22-017254:0
Canonical exit: 27 Dec 2022 (T+90)
25,000 shares@ US$4.1547.6% of flowCommon StockSEC:0001829126-22-017065:0
Canonical exit: 14 Dec 2022 (T+90)
2,500 shares@ US$4.1550.0% of flowCommon StockSEC:0001829126-22-017008:0
Canonical exit: 15 Dec 2022 (T+90)
36,000 shares@ US$4.1593.2% of flowCommon StockSEC:0001829126-22-017010:0
Canonical exit: 15 Dec 2022 (T+90)
25 of 28 declarations
关于 Nexalin Technology, Inc.
Nexalin Technology, Inc. (纳斯达克代码：NXL) 是一家在美国上市的医疗设备公司，总部位于美国德克萨斯州休斯顿，并在纳斯达克资本市场交易。Nexalin 最初于 2010 年注册为内华达州公司，后于 2021 年重组为特拉华州公司，专注于非侵入性神经刺激技术，旨在治疗精神健康和神经系统疾病。该公司的核心主张围绕专有的生物电子设备及其深度颅内频率刺激 (DIFS™) 平台，该公司将其描述为一种无需药物的方法，旨在影响大脑活动，而不依赖心理治疗作为主要干预手段。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001527352/000182912626002673/nexalintech_10k.htm?utm_source=openai)) 从运营角度来看，Nexalin 开发和商业化神经刺激产品，用于治疗焦虑、失眠和抑郁等适应症，同时日益将其临床叙事扩展到创伤性脑损伤、创伤后应激障碍 (PTSD)、阿尔茨海默病、痴呆症、注意力缺陷多动障碍 (ADHD) 和物质使用障碍。其产品组合和信息传递一直以 Gen-1 系统以及包括 Gen-2 SYNC 和 HALO™ 在内的新一代解决方案为中心，强调患者可用性、临床数据采集、远程监测和支持研究与治疗工作流程的虚拟诊所基础设施。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001527352/000182912626002673/nexalintech_10k.htm?utm_source=openai)) 在竞争方面，Nexalin 仍然是一个专业化且相对处于早期阶段的参与者，而不是一个规模化的商业医疗技术平台。其差异化优势在于知识产权、同行评审的临床出版物以及与美国 FDA 的监管合作。该公司力求将其 DIFS 技术定位为比更表面化的神经刺激方法更具循证性和更深层作用的替代方案，并强调其在物质使用障碍应用方面的美国专利保护是一项重要的战略资产。([nexalin.com](https://nexalin.com/nexalin-highlights-its-expanding-body-of-peer-reviewed-neuroimaging-research-confirming-its-difs-technology-as-the-leader-in-evidenced-based-non-invasive-brain-stimulation/?utm_source=openai)) 在地理上，Nexalin 的主要行政办公室位于德克萨斯州休斯顿，而投资者关系和过户代理支持则通过纽约管理。该公司的通讯还指出其国际业务活动，包括在美国和中国举行的领导层会议，这表明其扩张潜力不仅限于国内市场。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001527352/000182912626002673/nexalintech_10k.htm?utm_source=openai)) 近期发展一直是投资案例的核心。在 2025 年和 2026 年期间，Nexalin 报告了阿尔茨海默病方面的额外积极临床数据，发布了多项适应症的同行评审结果，推进了 HALO™ Clarity 的关键试验，获得了美国专利商标局对物质使用障碍的专利保护，并完成了其虚拟诊所和数字生态系统的一至五阶段。与此同时，该公司 2025 年的年度报告指出，其已遭受重大损失，并对其持续经营能力存在重大疑问，这凸显了资本获取和执行风险对投资者的重要性。([nexalin.com](https://nexalin.com/nexalin-technology-announces-completion-of-phases-one-through-five-of-its-virtual-clinic-and-digital-ecosystem-for-halo-clinical-research-and-patient-management/?utm_source=openai))
